Every 424B that CYTODYN INC (CYDY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CYDY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYDY filings page.
CytoDyn Inc. registered 794,972,289 shares of common stock for resale by selling stockholders: 410,046,456 shares of common stock and 384,925,833 shares underlying outstanding warrants. CytoDyn is not selling shares and will receive no proceeds from holders’ resales. If all covered warrants are exercised for cash, the company may receive up to approximately $94.6 million. CytoDyn intends to use proceeds from cash exercises for working capital and other general corporate purposes. Exercise prices range from $0.09387 to $0.50 per share; placement-agent warrants have a cashless exercise feature, while all other warrants do not.
Sales may occur in amounts and at prices chosen by the selling stockholders, and registration does not mean shares will be sold. Shares outstanding were 1,469,518,019 as of September 24, 2026. CytoDyn describes itself as a clinical-stage biotechnology company developing leronlimab for potential solid-tumor oncology applications; its strategy may include completing the Phase 2 CLOVER study in relapsed/refractory microsatellite stable colorectal cancer, exploring other solid-tumor indications, and pursuing strategic partnerships.
CytoDyn Inc. registers the resale of up to 278,076,375 shares of common stock. This prospectus covers 184,135,636 shares of common stock and 93,940,739 shares underlying outstanding warrants that may be sold from time to time by the named selling stockholders. The company is not offering any shares for its own account and will receive no proceeds from resale transactions, although it would receive cash proceeds if any of the registered warrants are exercised.
Shares outstanding were 1,369,733,680 as of May 15, 2026. The prospectus discloses that the company had approximately $11.6 million of unrestricted cash as of May 15, 2026 and that the selling stockholders control timing and amounts of any sales.
CytoDyn Inc. updates its prospectus supplement to register up to 375,999,668 shares of common stock, reflecting resale of 181,324,099 shares and 194,675,569 shares underlying warrants. This supplement incorporates CytoDyn’s Form 10-Q for the quarter ended February 28, 2026.
The company reported $15.7M in cash and cash equivalents and an accumulated deficit of $920.6M as of February 28, 2026, and the consolidated financials disclose substantial doubt about the company’s ability to continue as a going concern. The 10-Q records a legal settlement accrual revalued to $12.7M and an agreement in principle providing for $500,000 cash plus 49 million shares as a prospective class-action settlement, subject to documentation and court approval.
CytoDyn Inc. updates a prospectus supplement registering up to 375,999,668 shares of common stock for resale by selling stockholders. The supplement states this total comprises 181,324,099 shares offered directly and 194,675,569 shares underlying warrants.
The supplement incorporates a Form 8-K dated March 24, 2026, disclosing that the company extended two secured convertible promissory notes originally issued in 2021 by 36 months. As consideration, CytoDyn agreed to make monthly payments totalling $1,000,000 in shares (priced at the lower of the prior trading day close or a five-day average) through the new maturities in April 2029, and reduced the annual interest rate on each note to 5%.
CytoDyn files a prospectus supplement registering up to 375,999,668 shares of common stock for resale, consisting of 181,324,099 shares being resold and 194,675,569 shares issuable upon exercise of warrants. The supplement updates the Form S-1 prospectus and incorporates the Company’s Form 8-K disclosure dated February 27, 2026.
The 8-K discloses private financings completed in January–February 2026: a placement-agent-led private unit offering of approximately 81.4 million units for approximately $17.5 million, direct private sales including 3,944,773 shares for about $1.0 million, a SEPA issuance of ~0.8 million shares for ~$0.2 million, and convertible-note exchanges issuing ~5.9 million shares.
CytoDyn Inc. files a prospectus supplement covering the resale of up to 375,999,668 shares of common stock, including 181,324,099 outstanding shares and 194,675,569 shares issuable upon warrant exercise, by existing stockholders.
The supplement incorporates CytoDyn’s latest quarterly report for the period ended November 30, 2025, which shows cash and cash equivalents of $4.98 million, current liabilities of $85.11 million, total liabilities of $128.68 million, and a stockholders’ deficit of $119.75 million. The company reported a net loss of $22.61 million for the quarter and $28.15 million for the six-month period, and discloses that these conditions raise substantial doubt about its ability to continue as a going concern. CytoDyn outlines a standby equity purchase agreement of up to $30 million, significant outstanding convertible notes, and an agreement in principle to settle a securities class action with $500,000 in cash and 49 million shares.
CytoDyn Inc. is registering 375,999,668 shares of common stock for resale by existing investors, including 181,324,099 outstanding shares and 194,675,569 shares issuable upon exercise of warrants. The company itself is not selling shares and will receive no proceeds from stockholder sales, but could receive up to approximately $47.2 million if all covered warrants are exercised for cash. These shares stem from prior private placements, warrant and note transactions, and a 2024 warrant tender offer. CytoDyn is a clinical-stage biotechnology company developing its CCR5-targeting antibody leronlimab, with a focus on solid-tumor oncology. As of December 5, 2025, it reported approximately $4.2 million in unrestricted cash, about $16.7 million in accounts payable and accrued liabilities, a going concern audit opinion, and a highly volatile, penny-stock trading history.